Knight Therapeutics (KHTRF)
OTHER OTC:KHTRF
Want to see KHTRF full AI Analyst Report?
KHTRF Stock Chart & Stats
$5.57
-$0.05(-1.39%)
At close: 4:00 PM EST
$5.57
-$0.05(-1.39%)
Day’s Range― - ―
52-Week Range$3.93 - $5.64
Previous CloseN/A
Volume100.00
Average Volume (3M)896.00
Market Cap
$540.07M
Enterprise Value$737.86M
Total Cash (Recent Filing)$95.28M
Total Debt (Recent Filing)$77.91M
Price to Earnings (P/E)16.9
Beta0.03
Next Earnings
Aug 06, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding98,034,744
10 Day Avg. Volume1,740
30 Day Avg. Volume896
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)0.79
Price to Sales (P/S)1.34
P/FCF Ratio8.81
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue1.64
Enterprise Value/Gross Profit4.32
Enterprise Value/Ebitda14.37
Forecast
1Y Price Target
$6.59Price Target Upside18.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.13
Revenue Forecast (FY)$352.54M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Net Cash PositionLow leverage and an improved net cash position provide durable financial flexibility to fund launches, M&A and absorb earnings volatility. This conservatism supports multi-quarter execution (BD activity, buybacks, working capital) without relying on stressed external financing.
Proven Launch And BD Execution PipelineA repeatable launch capability and active business-development funnel create a structural revenue growth engine. Regular in‑licensing and multi-market launches diversify product timing risk and underpin medium-term revenue visibility and portfolio renewal.
Improving Cash Generation And Margin ExpansionSustained improvements in revenue, gross margin and operating cash inflows indicate stronger core cash generation. Higher adjusted EBITDA and stable gross margins support reinvestment, debt paydown and resilience across the 2–6 month horizon even if earnings mix shifts.
Bears Say
Inconsistent Profitability Over TimeRepeated swings between profit and loss show fragile operating leverage and unstable returns on equity. That inconsistency undermines predictability of earnings and cash available for reinvestment or returns, increasing execution risk over the medium term.
Regulatory Setback Delays Expected Product RevenueA 1–2 year delay for an in‑market filing materially defers anticipated revenues and alters pipeline timing. For a company relying on multiple launched assets, such regulatory slippage can compress near‑term growth and shift resource allocation across launches and markets.
LatAm Currency And Argentina Hyperinflation ExposureMeaningful exposure to Latin American currencies and potential hyperinflation accounting introduces a structural earnings and cashflow risk. Currency swings and accounting changes can materially alter reported revenue and margins across multiple quarters.
Knight Therapeutics News
KHTRF FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was $3.93 and its highest was $5.64 in the past 12 months.
What is Knight Therapeutics’s market cap?
Knight Therapeutics’s market cap is $540.07M.
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 91 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on May 07, 2026. The company reported $0.095 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.076.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 98,034,744 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of $0.095 in its last earnings report, beating expectations of $0.02. Following the earnings report the stock price went up 0.468%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in KHTRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Knight Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.59 (18.31% Upside)
$6.59 (18.31% Upside)
Insider Transactions
Sold Shares
Worth $174.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.85%
12-Months-Change
Fundamentals
Return on Equity
-0.69%
Trailing 12-Months
Asset Growth
13.90%
Trailing 12-Months
Company Description
Knight Therapeutics
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
KHTRF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum—record quarterly revenues and adjusted EBITDA, improved gross margin, a stronger balance sheet and an active launch and BD pipeline—supported by raised 2026 guidance. Key challenges include a withdrawal and delayed resubmission of Qelbree's Health Canada filing due to manufacturing changes, a meaningful YoY increase in operating expenses, a small Q1 net loss from investment revaluations, and medium-term risks from potential generic competition and Argentina hyperinflation exposure. Overall, the positive financial results, strengthened liquidity and well-filled launch pipeline materially outweigh the identifiable near-term execution and macro risks.View all KHTRF earnings summariesKHTRF Stock 12 Month Forecast
Average Price Target
$6.59
▲(18.31% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
Organigram Global
―
Aurora Cannabis
―
Cronos Group
―
HLS Therapeutics Inc
―
Ownership Overview
23.49% Insiders
3.69% Mutual Funds
0.09% Other Institutional Investors
71.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---